Efung Capital is one of the earliest private equity investment institutions developing venture capital businesses specializing in healthcare industry investment. Efung is composed of a high-caliber management team and an experienced investment team consisting of MDs/PhDs who graduated from top universities all over the world. For years, Efung Capital has been consistently pursuing the long-term value of biopharmaceuticals and high-end medical devices, including over 80 investment companies globally, such as Chipscreen Bioscience, Frontier Biotech, Ascentage Pharma, Lifotronic Technology, OBiO Technology , ASIERIS MediTech, 3D Medicines and Harbour BioMed et al. 

We have demonstrated a solid track record and achieved strong revenue and earnings growth. Leveraging its outstanding investment performance and exceptional research capabilities, Efung Capital has repeatedly earned industry acclaim, receiving numerous prestigious awards including Zero2IPO's Top 30 Medical & Health Investment Institutions of the Year and Top 100 Venture Capital Firms of the Year, ChinaVenture's Top 10 Best Exit Cases of the Year and Top 10 Biopharmaceutical Investment Institutions of the Year, Zero2IPO again for Top 30 Venture Capital Firms in the Greater Bay Area of the Year, Rongzhong's Top 100 Venture Capital Institutions of the Year, FOF Weekly's Top 30 Medical & Health Investment Institutions of the Year, and recognition as China's Most Dynamic Drug Innovation Investment Institution. The firm has also been named one of Shenzhen's Top 10 Venture Capital Institutions for multiple consecutive years and has been featured in an interview with Nature, one of the world's premier scientific journals.